July 05, 2018
1 min watch
Save

VIDEO: Allegro preps to move into phase 3 trial with DME treatment

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

NEWPORT BEACH, Calif. — Vicken Karageozian, MD, president and chief medical officer for Allegro Ophthalmics, discusses the progress of the company’s product Luminate, which is moving into phase 3 trials for the treatment of diabetic macular edema.